Metylprednisolon alltmer ifrågasatt vid behandling av akut ryggmärgsskada
(2005) In Läkartidningen 102(24-25). p.1887-1890- Abstract
Methylprednisolone (MP) has, through the results from the clinical multi-center studies National Acute Spinal Cord Injury Study II and III, during the 1990's become standard treatment in acute spinal cord injury (ASCI). Critical reappraisals of the data have later shown that analyses have been made on subgroups of the study-populations and argue that the results are based on statistical artefacts. This, combined with the failure to show improved functional recovery, puts into question earlier conclusions drawn on the efficacy of MP on ASCI. This review of the recent literature on the subject concludes that there is no scientific evidence to support MP as standard treatment in ASCI.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/643185db-e704-4c65-af3a-82c1684ba72d
- author
- Kronvall, Erik LU ; Sayer, Faisal T LU and Nilsson, Ola G LU
- alternative title
- Methylprednisolone in the treatment of acute spinal cord injury has become more and more questioned
- publishing date
- 2005-07-28
- type
- Contribution to specialist publication or newspaper
- publication status
- published
- subject
- keywords
- Acute Disease, Humans, Methylprednisolone/administration & dosage, Multicenter Studies as Topic, Neurologic Examination, Neuroprotective Agents/administration & dosage, Randomized Controlled Trials as Topic, Recovery of Function, Spinal Cord Injuries/drug therapy
- in
- Läkartidningen
- volume
- 102
- issue
- 24-25
- pages
- 1887 - 1890
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:16044768
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- no
- id
- 643185db-e704-4c65-af3a-82c1684ba72d
- alternative location
- http://www.lakartidningen.se/OldPdfFiles/2005/30335.pdf
- date added to LUP
- 2019-06-25 09:46:40
- date last changed
- 2021-09-23 04:04:47
@misc{643185db-e704-4c65-af3a-82c1684ba72d, abstract = {{<p>Methylprednisolone (MP) has, through the results from the clinical multi-center studies National Acute Spinal Cord Injury Study II and III, during the 1990's become standard treatment in acute spinal cord injury (ASCI). Critical reappraisals of the data have later shown that analyses have been made on subgroups of the study-populations and argue that the results are based on statistical artefacts. This, combined with the failure to show improved functional recovery, puts into question earlier conclusions drawn on the efficacy of MP on ASCI. This review of the recent literature on the subject concludes that there is no scientific evidence to support MP as standard treatment in ASCI.</p>}}, author = {{Kronvall, Erik and Sayer, Faisal T and Nilsson, Ola G}}, issn = {{0023-7205}}, keywords = {{Acute Disease; Humans; Methylprednisolone/administration & dosage; Multicenter Studies as Topic; Neurologic Examination; Neuroprotective Agents/administration & dosage; Randomized Controlled Trials as Topic; Recovery of Function; Spinal Cord Injuries/drug therapy}}, language = {{swe}}, month = {{07}}, number = {{24-25}}, pages = {{1887--1890}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Metylprednisolon alltmer ifrågasatt vid behandling av akut ryggmärgsskada}}, url = {{http://www.lakartidningen.se/OldPdfFiles/2005/30335.pdf}}, volume = {{102}}, year = {{2005}}, }